Chapin Davis Inc. Purchases New Shares in Danaher Corporation $DHR

Chapin Davis Inc. acquired a new stake in Danaher Corporation (NYSE:DHR) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,319 shares of the conglomerate’s stock, valued at approximately $957,000.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Danaher in the 2nd quarter valued at $10,492,520,000. Jupiter Topco LLC purchased a new position in Danaher during the 2nd quarter worth $1,456,317,000. Generation Investment Management LLP purchased a new position in Danaher during the 2nd quarter worth $1,287,949,000. Bank of America Corp DE acquired a new position in Danaher in the second quarter valued at $993,846,000. Finally, Legal & General Group Plc purchased a new stake in shares of Danaher in the second quarter valued at about $801,056,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

Danaher stock opened at $217.33 on Friday. The company has a market cap of $152.78 billion, a P/E ratio of 38.60, a price-to-earnings-growth ratio of 2.72 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The business has a fifty day moving average of $210.88 and a two-hundred day moving average of $194.44. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the firm posted $0.77 EPS. The business’s revenue was up 5.5% compared to the same quarter last year. As a group, analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

Analyst Ratings Changes

A number of research firms recently issued reports on DHR. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Piper Sandler assumed coverage on Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 price target for the company. Barclays lifted their price objective on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday. UBS Group initiated coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price on the stock. Finally, Evercore restated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $235.23.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.